PTPRC and leukemia: Orozco JJ and colleagues have reported that recipients conditioned with a β-emitter yttrium-90 (90Y) conjugated to an anti-CD45 mAb combined with pre- and posttransplant Cy in the absence of TBI or fludarabine facilitated high levels of haploidentical BM engraftment and improved survival in a murine leukemia model (68).